METTL18: A Potential Drug Target and Biomarker (G92342)

Target Name: METTL18

NCBI ID: G92342

METTL18

METTL18: A Potential Drug Target and Biomarker

Methyltransferase-like protein 18 (METTL18) is a protein that plays a crucial role in the regulation of gene expression and DNA methylation. METTL18 is a nuclear protein that is composed of 21 kDa monomers. It is highly conserved in various species, including humans, and has a significant role in various cellular processes, including DNA replication, transcription, and gene regulation. METTL18 has also been implicated in the development and progression of various diseases, including cancer. Therefore, understanding the function of METTL18 and its potential as a drug target or biomarker is of great interest.

Functional Analysis of METTL18

METTL18 is a protein that is involved in the regulation of gene expression and DNA methylation. It is a key player in the process of DNA replication, as it is required for the transfer of methyl groups from the DNA template to the newly synthesized DNA strand. METTL18 is also involved in the regulation of transcription, as it can interact with the RNA polymerase II complex to prevent the access of transcription factors to the start site of the gene.

In addition to its role in DNA replication and transcription, METTL18 is also involved in the regulation of cell cycle progression. It is a component of the G1 phase-specific protein complex, which is responsible for regulating the entry of cells into the G1 phase of the cell cycle. METTL18 is also involved in the regulation of the G2 phase, as it is required for the progression of cells from the G2 to the M phase of the cell cycle.

METTL18 and Cancer

The regulation of gene expression and DNA methylation is a crucial aspect of cancer development, and METTL18 is involved in both processes. Several studies have shown that METTL18 is involved in the regulation of the expression of cancer-related genes, including PIK3CA, PTEN, and NEDD8. METTL18 has also been shown to play a role in the regulation of cell cycle progression, which is a critical aspect of cancer development.

In addition to its involvement in cancer development, METTL18 has also been implicated in the regulation of normal cell growth and differentiation. It is involved in the regulation of cell adhesion, as it is a component of the cadherin complex, which is responsible for the regulation of cell-cell adhesion. METTL18 is also involved in the regulation of cell proliferation, as it is required for the growth and proliferation of cells.

Potential as a Drug Target

The regulation of gene expression and DNA methylation is a crucial aspect of various diseases, including cancer. Therefore, the potential of METTL18 as a drug target or biomarker is of great interest. METTL18 can be targeted by small molecules, such as inhibitors of DNA methylation or RNA polymerase II, which can inhibit its function in the regulation of gene expression and DNA methylation.

In addition to its potential as a drug target, METTL18 has also been shown to be a potential biomarker for various diseases, including cancer. The regulation of gene expression and DNA methylation is a critical aspect of cancer development, and therefore, the expression of METTL18 is a reliable indicator of the presence of cancer. Additionally, the regulation of DNA methylation is also a critical aspect of normal cell growth and development, and METTL18 is involved in this process

Protein Name: Methyltransferase Like 18

Functions: Protein-L-histidine N-tele-methyltransferase that specifically monomethylates RPL3, thereby regulating translation elongation (PubMed:23349634, PubMed:33693809, PubMed:35674491). Histidine methylation of RPL3 regulates translation elongation by slowing ribosome traversal on tyrosine codons: slower elongation provides enough time for proper folding of synthesized proteins and prevents cellular aggregation of tyrosine-rich proteins (PubMed:35674491)

The "METTL18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets